In 2023, Li et al. reported that CD8 + T cells were significantly correlated with clinical outcomes in HNSCC patients, with the following top five mutated genes confirmed in a cohort in The Cancer Genome Atlas: CDKN2A, FAT1, MUC16, TP53, and TTN. This evidence concerns the gene CDKN2A and head and neck squamous cell carcinoma.